Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 45 molecules. Out of which approximately 41 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Drugs In Development, 2022, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 13, 3, 7, 1, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Report covers products from therapy areas Immunology, Hematological Disorders, Central Nervous System, Gastrointestinal, Infectious Disease, Ophthalmology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Musculoskeletal Disorders, Undisclosed, Oncology, Other Diseases and Respiratory which include indications Paroxysmal Nocturnal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Neuromyelitis Optica (Devic’s Syndrome), Autoimmune Disorders, Chronic Inflammation, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Lupus Nephritis, Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury, Geographic Atrophy, Guillain-Barre Syndrome, Thrombotic Microangiopathy, Unspecified, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dermatomyositis, IgA Nephropathy (Berger's Disease), Kidney Disease (Nephropathy), Unspecified Immunological Disorders, Uveitis, Acute Lung Injury, Age Related Macular Degeneration, Amyotrophic Lateral Sclerosis, Antiphospholipid Syndrome, Asthma, Atopic Keratoconjunctivitis, Bacterial Sepsis, Bullous Pemphigoid, Cardiovascular Inflammation, Choroidal Neovascularization, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hematuria, Hemorrhagic Shock, Hidradenitis Suppurativa, Intermediate Uveitis, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Lung Disease, Microscopic Polyangiitis (MPA), Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Non-infectious Uveitis, Posterior Uveitis, Primary Progressive Multiple Sclerosis (PPMS), Proteinuria, Pyoderma Gangrenosum, Rheumatoid Arthritis, Sepsis, Septic Shock, Sickle Cell Disease With Vaso-Occlusive Crisis, Squamous Cell Carcinoma, Subarachnoid Hemorrhage, Sudoriferous (Sweat) Gland Disorders, Trauma, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome) and Unspecified Ophthalmological Disorders.

Furthermore, this report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Overview
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Companies Involved in Therapeutics Development
Adienne Pharma & Biotech SA
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Aptarion Biotech AG
Biocad
CANbridge Life Sciences Ltd
Chugai Pharmaceutical Co Ltd
Generium
ImmunAbs Inc
InflaRx NV
ISU ABXIS Co Ltd
IVERIC bio Inc
Kira Pharmaceuticals
Navigen Inc
Novartis AG
NovelMed Therapeutics Inc
Prestige BioPharma Ltd
Ra Pharmaceuticals Inc
Rallybio Corp
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Sirnaomics Ltd
Staidson (Beijing) Biopharmaceuticals Co Ltd
Staidson BioPharma Inc
Tasly Biopharmaceuticals Co Ltd
Vertex Pharmaceuticals Inc
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Drug Profiles
AOND-21 – Drug Profile
avacincaptad pegol sodium – Drug Profile
B-20672 – Drug Profile
BDB-001 – Drug Profile
Bikaciomab – Drug Profile
CAN-106 – Drug Profile
cemdisiran – Drug Profile
Coversin LA – Drug Profile
crovalimab – Drug Profile
eculizumab – Drug Profile
eculizumab biosimilar – Drug Profile
gefurulimab – Drug Profile
IFX-002 – Drug Profile
IM-101 – Drug Profile
Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration – Drug Profile
Mubodina – Drug Profile
Neuromyelitis optica spectrum disorder – Drug Profile
NM-9405 – Drug Profile
nomacopan – Drug Profile
P-014 – Drug Profile
Peptide to Inhibit C3a, C4a and C5a for Fibrosis and Ophthalmology – Drug Profile
pozelimab – Drug Profile
Protein to Inhibit Complement C5 for Immunology – Drug Profile
RA-101295 – Drug Profile
ravulizumab LA – Drug Profile
Recombinant Enzyme to Inhibit C3a and C5a for Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis – Drug Profile
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis – Drug Profile
RLYB-114 – Drug Profile
RLYB-116 – Drug Profile
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria – Drug Profile
STP-145G – Drug Profile
STP-247G – Drug Profile
STSA-1002 – Drug Profile
Synthetic Coversin – Drug Profile
Synthetic Peptide to Inhibit Complement 5a for Unspecified Indication – Drug Profile
Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation – Drug Profile
tesidolumab – Drug Profile
vilobelimab – Drug Profile
zilucoplan – Drug Profile
zilucoplan XR – Drug Profile
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Dormant Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Discontinued Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Product Development Milestones
Featured News & Press Releases
Sep 27, 2022: Iveric Bio to present top-line results for avacincaptad pegol from phase 3 GATHER2 clinical trial in geographic atrophy at AAO 2022 Annual Meeting
Sep 26, 2022: EC approves Alexion’s Ultomiris for generalised myasthenia gravis
Sep 22, 2022: CANbridge Pharmaceuticals data on CAN106 to be presented at two conferences
Sep 09, 2022: InflaRx to present at upcoming scientific and investor conferences
Sep 08, 2022: Inflarx announces vilobelimab phase III results in critically ill covid-19 patients published in The Lancet Respiratory Medicine
Sep 06, 2022: Iveric Bio announces positive topline data from Zimura GATHER2 phase 3 clinical trial in geographic atrophy
Aug 29, 2022: Alnylam eports positive results from phase 2 study of investigational Cemdisiran for the treatment of IgA Nephropathy
Aug 26, 2022: Kira Pharmaceuticals to present new preclinical data on lead asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
Aug 25, 2022: Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis
Aug 24, 2022: Amgen reports positive data from Phase III trial of biosimilar for PNH
Aug 10, 2022: Anti-C5 recycling antibody crovalimab obtains priority review in china for the treatment of paroxysmal nocturnal hemoglobinuria
Aug 03, 2022: ImmunAbs announces US FDA approval for a phase 1 clinical trial
Aug 01, 2022: Akari Therapeutics narrows pipeline focus
Jul 28, 2022: Kira Pharmaceuticals receives FDA Orphan Drug Designation for KP104, a bifunctional antibody fusion protein, for the treatment of Paroxysmal Nocturnal Hemoglobinuria
Jul 28, 2022: Akari Therapeutics announces positive results from recent pre-clinical studies of investigational PASylated nomacopan that support the potential to advance research toward IND/IMPD for clinical trials in geographic atrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indications, 2022
Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
Table 5: Number of Products under Development by Indications, 2022 (Contd..2)
Table 6: Number of Products under Development by Companies, 2022
Table 7: Number of Products under Development by Companies, 2022 (Contd..1)
Table 8: Products under Development by Companies, 2022
Table 9: Products under Development by Companies, 2022 (Contd..1)
Table 10: Products under Development by Companies, 2022 (Contd..2)
Table 11: Products under Development by Companies, 2022 (Contd..3)
Table 12: Products under Development by Companies, 2022 (Contd..4)
Table 13: Products under Development by Companies, 2022 (Contd..5)
Table 14: Products under Development by Companies, 2022 (Contd..6)
Table 15: Products under Development by Companies, 2022 (Contd..7)
Table 16: Products under Development by Companies, 2022 (Contd..8)
Table 17: Number of Products under Investigation by Universities/Institutes, 2022
Table 18: Products under Investigation by Universities/Institutes, 2022
Table 19: Number of Products by Stage and Mechanism of Actions, 2022
Table 20: Number of Products by Stage and Route of Administration, 2022
Table 21: Number of Products by Stage and Molecule Type, 2022
Table 22: Pipeline by Adienne Pharma & Biotech SA, 2022
Table 23: Pipeline by Akari Therapeutics Plc, 2022
Table 24: Pipeline by Alexion Pharmaceuticals Inc, 2022
Table 25: Pipeline by Alnylam Pharmaceuticals Inc, 2022
Table 26: Pipeline by Amgen Inc, 2022
Table 27: Pipeline by Aptarion Biotech AG, 2022
Table 28: Pipeline by Biocad, 2022
Table 29: Pipeline by CANbridge Life Sciences Ltd, 2022
Table 30: Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Table 31: Pipeline by Generium, 2022
Table 32: Pipeline by ImmunAbs Inc, 2022
Table 33: Pipeline by InflaRx NV, 2022
Table 34: Pipeline by ISU ABXIS Co Ltd, 2022
Table 35: Pipeline by IVERIC bio Inc, 2022
Table 36: Pipeline by Kira Pharmaceuticals, 2022
Table 37: Pipeline by Navigen Inc, 2022
Table 38: Pipeline by Novartis AG, 2022
Table 39: Pipeline by NovelMed Therapeutics Inc, 2022
Table 40: Pipeline by Prestige BioPharma Ltd, 2022
Table 41: Pipeline by Ra Pharmaceuticals Inc, 2022
Table 42: Pipeline by Rallybio Corp, 2022
Table 43: Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 44: Pipeline by Samsung Bioepis Co Ltd, 2022
Table 45: Pipeline by Sirnaomics Ltd, 2022
Table 46: Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2022
Table 47: Pipeline by Staidson BioPharma Inc, 2022
Table 48: Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Table 49: Pipeline by Vertex Pharmaceuticals Inc, 2022
Table 50: Dormant Products, 2022
Table 51: Dormant Products, 2022 (Contd..1)
Table 52: Dormant Products, 2022 (Contd..2)
Table 53: Dormant Products, 2022 (Contd..3)
Table 54: Dormant Products, 2022 (Contd..4)
Table 55: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Routes of Administration, 2022
Figure 6: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 7: Number of Products by Molecule Types, 2022
Figure 8: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings